Gain Therapeutics, Inc.

The year 2025 is set top be a pivotal one for the biopharma industry, marked by significant political changes in the US and beyond. Around half the world’s population live in countries that held natio

Anti-inflammatory drugs have come a long way since the advent of corticosteroids. While they marked a pivotal moment in the 20th century for managing devastating inflammation, non-steroidal anti-infla

It has been a challenging month for Bethesda, Maryland-based Gain Therapeutics, Inc. Shares of the company have fallen dramatically since 14 June, when it priced a public offering to raise $11m. The

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Gain, Zentalis Hope To Find Protein Mis